Catalent Announces Secondary Public Offering Of Common Stock

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (“Catalent”) (NYSE:CTLT), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced the launch of a secondary public offering of its common stock. Certain stockholders of Catalent (the “Selling Stockholders”) are offering for sale to the public all of the approximately 19.0 million shares of Catalent’s common stock owned by them. Catalent is not offering any stock in this transaction and will not receive any proceeds from the sale of the shares by the Selling Stockholders.

Goldman, Sachs & Co., Deutsche Bank Securities and Morgan Stanley are acting as underwriters for the offering.

This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities described above, nor shall there be any sale of such shares of common stock in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

The offering of the shares of common stock will be made pursuant to an effective shelf registration statement. The offering will be made only by means of a prospectus, copies of which may be obtained from Goldman, Sachs & Co., Attn: Prospectus Department, 200 West Street, New York, NY 10282, telephone:1-866-471-2526, facsimile: 212-902-9316, e-mail: prospectus-ny@ny.email.gs.com; Deutsche Bank Securities Inc., Attention: Prospectus Group, 60 Wall Street, New York, New York 10005, telephone: (800) 503-4611 or email prospectus.cpdg@db.com; or Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014. The registration statement is available on the SEC’s website at www.sec.gov under the registrant’s name.

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. You can identify these forward-looking statements by the use of words such as “outlook,” “believes,” “expects,” “potential,” “continues,” “may,” “will,” “should,” “could,” “seeks,” “projects,” “predicts,” “intends,” “plans,” “estimates,” “anticipates” or the negative version of these words or other comparable words and include all discussions of the contemplated secondary public offering. Such forward-looking statements are subject to various risks and uncertainties, including (a) any decision by the Selling Stockholders or the underwriters not to proceed with the proposed secondary offering, (b) market conditions making the secondary offering unattractive to potential purchasers of the offered shares of common stock, and (c) those risks and uncertainties described under the section entitled “Part I —Item 1A. Risk Factors” of Catalent’s Annual Report on Form 10-K for the fiscal year ended June 30, 2016, filed with the SEC, as such factors may be updated from time to time in Catalent’s periodic filings with the SEC, which are accessible on the SEC’s website at www.sec.gov. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in Catalent’s filings with the SEC. Catalent undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by law.